Navigation Links
Mouse model for mesothelioma reproduces human disease
Date:3/10/2008

Scientists have established a mouse model for human malignant mesothelioma (MM) that will provide valuable insight into cancer development and progression along with new directions for design of therapeutic strategies. The research, published by Cell Press in the March issue of Cancer Cell, may eventually lead to a substantially improved outlook for patients with this devastating disease.

MM is an aggressive cancer originating from the mesothelial lining of the pleural cavity. MM is associated with asbestos exposure and is characterized by a long latency period between exposure and disease onset. Chemotherapy can sometimes lead to improvement of overall survival but there is no cure for MM and patients often succumb from the disease within a year of diagnosis. There is an urgent need for experimental models of MM that can be used to not only study the onset and progression of the disease, but also to serve as a model to select new combination therapies and targeted agents, says study leader, Dr. Anton Berns, from The Netherlands Cancer Institute.

In humans, MM has been associated with genetic lesions that result in the loss of Neurofibromatosis type 2 (NF2) and genetic lesions affecting RB and P53 pathways. Dr. Berns team investigated whether a range of conditional single or compound mutations in the Nf2, p53 and Rb pathways within the mesothelial lining of the thoracic cavity would cause MM in mice.

The researchers found that the vast majority of mice with conditional Nf2;Ink4a/Arf and Nf2;p53 mutations developed MM after a short latency period. The mouse MM tumors, which could be followed noninvasively through the use of bioluminescence imaging, closely resembled human MM. Interestingly, Nf2;Ink4a/Arf knockout mice had a more invasive cancer when compared with Nf2;p53 knockout mice. The researchers went on to show that the loss of Ink4a makes a substantial contribution to the poor clinical outcome of murine MM.

These res
'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Mouse study: Real-time imaging device may improve surgery for congenital colon disease
2. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
3. Mouse Model of Age-Related Macular Degeneration Developed
4. Gene Tweak Reverses Aging in Mouse Skin Cells
5. A longer-living, healthier mouse that could hold clues to human aging
6. Mouse mammary tumor virus can replicate in human cells
7. Mouse Study Gives Clues to Colitis
8. Mouse vision has a rhythm all its own
9. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
10. Liko Introduces New LowBase(TM) Model of Its Popular Golvo Mobile Lift
11. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Nurses Report Quality Health Benefits Key to Choosing an Employer 2Health News:Pilot Program Successfully Addresses Mental Health Issues in Pennsylvania's Children 2Health News:First Patients Treated in Italy With the Percutaneous MitraClip(R) System 2Health News:First Patients Treated in Italy With the Percutaneous MitraClip(R) System 3Health News:Become Mariah Carey's Personal Fashion Designer! 2Health News:Become Mariah Carey's Personal Fashion Designer! 3Health News:Become Mariah Carey's Personal Fashion Designer! 4Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 2Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 3Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 4Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 5Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 6Health News: Booz & Company Study Finds Top Corporate Spenders on R&D Boosted Investments to Nearly Half a Trillion Dollars in 2007 7
Breaking Medicine Technology:Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2CryoLife Provides Initial 2010 Financial Guidance 6633 1CryoLife Provides Initial 2010 Financial Guidance 6633 2CryoLife Provides Initial 2010 Financial Guidance 6633 3CryoLife Provides Initial 2010 Financial Guidance 6633 4CryoLife Provides Initial 2010 Financial Guidance 6633 5MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 6627 1Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 6627 2